Liposomal chemotherapy CPX-351: safety profile - 101793

Spotlight
Video

Liposomal chemotherapy CPX-351: safety profile

VJHemOnc has 1533 videos Subscribe Here

Loading........
Description: CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two types of secondary acute myeloid leukemia (AML). Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the safety profile of this exciting drug.
Shared By : VJHemOnc
Posted on : 03/08/18
Added : 7 months ago